Eversept Partners LP Raises Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Eversept Partners LP grew its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 12.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 779,998 shares of the company's stock after purchasing an additional 88,766 shares during the quarter. Viridian Therapeutics comprises about 1.3% of Eversept Partners LP's portfolio, making the stock its 15th biggest position. Eversept Partners LP owned approximately 0.98% of Viridian Therapeutics worth $14,953,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in VRDN. J. Safra Sarasin Holding AG bought a new stake in Viridian Therapeutics in the fourth quarter valued at $699,000. Tower Research Capital LLC TRC grew its stake in shares of Viridian Therapeutics by 824.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 34,172 shares of the company's stock valued at $655,000 after buying an additional 30,475 shares during the period. MetLife Investment Management LLC increased its position in Viridian Therapeutics by 21.8% in the 4th quarter. MetLife Investment Management LLC now owns 44,295 shares of the company's stock valued at $849,000 after buying an additional 7,914 shares in the last quarter. Farringdon Capital Ltd. acquired a new position in Viridian Therapeutics during the 4th quarter worth approximately $329,000. Finally, XTX Topco Ltd bought a new position in Viridian Therapeutics in the fourth quarter worth approximately $440,000.

Viridian Therapeutics Stock Performance

Shares of NASDAQ VRDN traded down $0.06 during midday trading on Friday, reaching $13.50. The company's stock had a trading volume of 524,676 shares, compared to its average volume of 1,200,464. The stock has a market capitalization of $1.10 billion, a P/E ratio of -3.13 and a beta of 0.81. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The firm has a 50 day moving average price of $14.24 and a 200-day moving average price of $18.27. Viridian Therapeutics, Inc. has a 12-month low of $9.90 and a 12-month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, topping analysts' consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.05 million. As a group, equities analysts predict that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Analyst Ratings Changes

VRDN has been the subject of several research reports. HC Wainwright reissued a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research report on Wednesday. Needham & Company LLC restated a "buy" rating and issued a $38.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Viridian Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $35.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.